Growing Burden of Non-Communicable Diseases in the Emerging Health Markets: The Case of BRICS

Frontiers in Public Health

Volumn 3, Issue , 2015, Pages

  Jakovljevic, Mihajlo B ^a   Milovanovic, Olivera ^a  

^a University of Kragujevac Medical Faculty   (Serbia)

Author keywords

BRICS; emerging market; financing; health care; N 11; non communicable disease; sustainability

Indexed keywords

EID: 84995525594     PISSN: None     EISSN: 22962565     Source Type: Journal    
DOI: 10.3389/fpubh.2015.00065     Document Type: Article

References (46)

1. Kuh D Ben-Shlomo Y. A Life Course Approach to Chronic Disease Epidemiology. New York, NY: Oxford University Press (2004).
2. Chopra M Galbraith S Darnton-Hill I. A global response to a global problem: the epidemic of overnutrition. Bull World Health Organ (2002) 80(12):952–8.12571723
3. Jakovljevic M Laaser U. Long term population aging 1950-2010 in seventeen transition countries in the wider region of South East Europe. SEEJPH (2015) 3.10.12908/SEEJPH-2014-42
4. Ogura S Jakovljevic M. Health financing constrained by population aging – an opportunity to learn from Japanese experience. Ser J Exp Clin Res (2014) 15:175–81.10.2478/SJECR
5. Beaglehole R Yach D. Globalisation and the prevention and control of non-communicable disease: the neglected chronic diseases of adults. Lancet (2003) 362(9387):903–8.10.1016/S0140-6736(03)14335-813678979
6. Schmidt MI Duncan BB Menezes AM Monteiro CA Barreto SM Chor D et al. Chronic non-communicable diseases in Brazil: burden and current challenges. Lancet (2011) 377(9781):1949–61.10.1016/S0140-6736(11)60135-921561658
7. Jakovljevic MB. The key role of the leading emerging BRIC markets in the future of global health care. Ser J Exp Clin Res (2014) 15(3):139–43.10.5937/sjecr1403139J
8. Watt NF Gomez EJ McKee M. Global health in foreign policy – and foreign policy in health? Evidence from the BRICS. Health Policy Plan (2013) 2013:1–11.10.1093/heapol/czt06324072881
9. Goldman S Bloomberg. Goldman Sachs’s MIST Topping BRICs as Smaller Markets Outperform. Available from: http://www.bloomberg.com/news/2012-08-07/goldman-sachs-s-mist-topping-brics-as-smaller-markets-outperform.html
10. Ghaffar A Reddy KS Singhi M. Burden of non-communicable diseases in South Asia. BMJ (2004) 328(7443):807–10.10.1136/bmj.328.7443.807
11. Dans A Ng N Varghese C Tai ES Firestone R Bonita R. The rise of chronic non-communicable diseases in Southeast Asia: time for action. Lancet (2011) 377(9766):680–9.10.1016/S0140-6736(10)61506-121269677
12. Jakovljevic MB. Resource allocation strategies in Southeastern European health policy. Eur J Health Econ (2013) 14(2):153–9.10.1007/s10198-012-0439-y23143312
13. Rahim A Sibai A Khader Y Hwalla N Fadhil I Alsiyabi H et al. Non-communicable diseases in the Arab world. Lancet (2014) 383(9914):356–67.10.1016/S0140-6736(13)62383-1
14. Popkin BM Horton S Kim S Mahal A Shuigao J. Trends in diet, nutritional status, and diet-related noncommunicable diseases in China and India: the economic costs of the nutrition transition. Nutr Rev (2001) 59(12):379–90.10.1111/j.1753-4887.2001.tb06967.x11766908
15. Kumagai N Ogura S. Persistence of physical activity in middle age: a nonlinear dynamic panel approach. Eur J Health Econ (2014) 15(7):717–35.10.1007/s10198-013-0518-823860736
16. Bloom DE Cafiero E Jané-Llopis E Abrahams-Gessel S Bloom LR Fathima S et al. The global economic burden of noncommunicable diseases (No. 8712). Program on the Global Demography of Aging (2012). Available from: https://ideas.repec.org/p/gdm/wpaper/8712.html
17. Yang G Kong L Zhao W Wan X Zhai Y Chen LC et al. Emergence of chronic non-communicable diseases in China. Lancet (2008) 372(9650):1697–705.10.1016/S0140-6736(08)61366-518930526
18. Mahal A Karan A Engelgau M. The Economic Implications of Non-Communicable Disease for India. Washington, DC: World Bank (2010). Available from: https://openknowledge.worldbank.com/handle/10986/13649 [License: CC BY 3.0 Unported]
19. Boutayeb A. The double burden of communicable and non-communicable diseases in developing countries. Trans R Soc Trop Med Hyg (2006) 100(3):191–9.10.1016/j.trstmh.2005.07.02116274715
20. Alwan A. Global Status Report on Non-Communicable Diseases 2010. World Health Organization (2011). Available from: http://www.who.int/nmh/publications/ncd_report_full_en.pdf
21. Beaglehole R Bonita R Alleyne G Horton R Li L Lincoln P et al. UN high-level meeting on non-communicable diseases: addressing four questions. Lancet (2011) 378(9789):449–55.10.1016/S0140-6736(11)60879-921665266
22. Gwatkin DR Guillot M Heuveline P. The burden of disease among the global poor. Lancet (1999) 354(9178):586–9.10.1016/S0140-6736(99)02108-X
23. Lee K Chagas LC Novotny TE. Brazil and the framework convention on tobacco control: global health diplomacy as soft power. PLoS Med (2010) 7(4):e1000232.10.1371/journal.pmed.1000232
24. Jakovljevic MB Jovanovic M Nikic K Dejanovic SD Radovanovi A Pirkovic I et al. Acute alcohol detoxification costs in upper-middle income: Western Balkans. J Health Behav Public Health (2011) 1(2):1–7.
25. Alwan A MacLean DR Riley LM d’Espaignet ET Mathers CD Stevens GA et al. Monitoring and surveillance of chronic non-communicable diseases: progress and capacity in high-burden countries. Lancet (2010) 376(9755):1861–8.10.1016/S0140-6736(10)61853-321074258
26. WHO Global Coordination. Mechanism on the Prevention and Control of NCDs. Available from: http://www.who.int/nmh/ncd-coordination-mechanism/background/en/
27. Revill P Sculpher M. Cost effectiveness of interventions to tackle non-communicable diseases. BMJ (2012) 344:e609.10.1136/bmj.d7883
28. Cerqueira MT Cravioto A Dianis N Ghannem H Levitt N Yan N et al. Global response to non-communicable disease. BMJ (2011) 342:d3823.10.1136/bmj.d3823
29. Salomon JA Carvalho N Gutiérrez-Delgado C Orozco R Mancuso A Hogan DR et al. Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis. BMJ (2012) 344:e614.10.1136/bmj.e35522389335
30. Rodin J de Ferranti D. Universal health coverage: the third global health transition? Lancet (2012) 380(9845):861–2.10.1016/S0140-6736(12)61340-3
31. Allotey P Reidpath DD Yasin S Chan CK de-Graft Aikins A. Rethinking health-care systems: a focus on chronicity. Lancet (2011) 377(9764):450–1.10.1016/S0140-6736(10)61856-9
32. Boytsov S Potemkina RA. Perspectives: preventive measures for public health in Russian Federation. Eur Heart J (2014) 16(Suppl A):A84–6.10.1093/eurheartj/sut018
33. Jakovljevic M Gutzwiller F Schwenkglenks M Milovanovic O Rancic N Varjacic M et al. Costs differences among monoclonal antibodies-based first-line oncology cancer protocols for breast cancer, colorectal carcinoma and non-Hodgkin’s lymphoma. J BUON (2014) 19(3):1111–20.25536624
34. Sposato LA Esnaola MM Zamora R Zurrú MC Fustinoni O Saposnik G. Quality of ischemic stroke care in emerging countries the Argentinian National Stroke Registry (ReNACer). Stroke (2008) 39(11):3036–41.10.1161/STROKEAHA.108.52106218703802
35. Lazic Z Gajovıc O Tanaskovic I Milovanovic D Atanasijevic D Jakovljevic MB. GOLD stage impact on COPD direct medical costs in elderly. J Health Behav Public Health (2012) 2(3):1–7.
36. Biorac N Jakovljević MB Stefanović D Perović S Janković S. Assessment of diabetes mellitus type 2 treatment costs in the Republic of Serbia. Vojnosanit Pregl (2009) 66(4):271–6.10.2298/VSP0904271B19432292
37. Jakovljevic M Djordjevic N Jurisevic M Jankovic S. Evolution of Serbian pharmaceutical market alongside socioeconomic transition. Expert Rev Pharmacoecon Outcomes Res (2015) 15(3):1–10.10.1586/14737167.2015.100304425592856
38. Ranković A Rančić N Jovanović M Ivanović M Gajović O Lazić Z et al. Impact of imaging diagnostics on the budget: are we spending too much? Vojnosanit Pregl (2013) 70(7):709–11.
39. Jakovljević M Ranković A Rančić N Jovanović M Ivanović M Gajović O et al. Radiology services costs and utilization patterns estimates in Southeastern Europe – a retrospective analysis from Serbia. Value Health Reg Issues (2013) 2(2):218–25.10.1016/j.vhri.2013.07.002
40. Jakovljevic MB. Oncology monoclonal antibodies expenditure trends and reimbursement projections in the emerging Balkan market. Farmeconomia Health Econ Ther Pathw (2014) 15(1):27–32.10.7175/fe.v15i1.909
41. Jakovljevic M Zugic A Rankovic A Dagovic A. Radiation therapy remains the key cost driver of oncology inpatient treatment. J Med Econ (2015) 18(1):29–36.10.3111/13696998.2014.97116225268728
42. Jakovljevic MB. Health expenditure dynamics in Serbia 1995-2012. Hosp Pharmacol (2014) 1(3):180–3.
43. Wang Q Brenner S Leppert G Banda TH Kalmus O De Allegri M. Health seeking behaviour and the related household out-of-pocket expenditure for chronic non-communicable diseases in rural Malawi. Health Policy Plan (2015) 30(2):242–52.10.1093/heapol/czu00424561879
44. Jakovljevic MB Jovanovic M Lesch OM. Accessibility and affordability of alcohol dependency medical care in Serbia. Front Psychiatry (2014) 5:192.10.3389/fpsyt.2014.00192
45. McGranahan G Martine G. Urbanization and Development: Policy Lessons from the BRICS Experience. London (2012). Available from: http://pubs.iied.org/pdfs/10622IIED.pdf
46. Kickbusch I. BRICS’ contributions to the global health agenda. Bull World Health Organ (2014) 92(6):463–4.10.2471/BLT.13.127944